mAbxience Sandoz emicizumab biosimilar collaboration
Analysis based on 9 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The deal modestly strengthens the biosimilar growth narrative for Novartis — Sandoz and its parent-linked shareholder Fresenius (company), while adding pipeline depth for privately held mAbxience and Insud Pharma. Financial terms were not disclosed, so near-term earnings impact is limited and the market reaction is likely to be contained to sentiment around biosimilar pipeline expansion.
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for the treatment of hemophilia A. Under the agreement, mAbxience will be responsible for development and manufacturing of the biosimilar through its GMP-approved facilities in Spain and Argentina, while Novartis — Sandoz will hold exclusive commercialization rights globally, excluding Argentina, Uruguay, and Paraguay. Financial terms of the agreement remain confidential. The emicizumab reference market is estimated at approximately USD 5.7 billion, and hemophilia A accounts for around 80% of all hemophilia cases worldwide. Jurgen Van Broeck, Chief Executive Officer of mAbxience, said the agreement recognizes mAbxience's development and manufacturing platform and combines it with Novartis — Sandoz's global biosimilars reach. The deal expands mAbxience's pipeline into hemophilia A and rare diseases, complementing a biosimilar pipeline spanning oncology, immunology, and bone diseases, and comes as healthcare systems prepare for a wave of biologic medicines losing exclusivity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard